(+)-Buxabenzamidienine



Compound IDCDAMM02654
Common name(+)-Buxabenzamidienine
IUPAC nameN-[15-[1-(dimethylamino)ethyl]-7,7,12,16-tetramethyl-6-tetracyclo[9.7.0.03,8.012,16]octadeca-1(18),2-dienyl]benzamide
Molecular formulaC33H48N2O

Experimental data

Retention time13.15
Adduct[M+H]+
Actual mz489.386
Theoretical mz489.384
Error3.73
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.4584

Identifiers and class information

Inchi keyPDEYVCIISSAEBG-UECJVQBINA-N
SmilesO=C(NC1CCC2=CC3=CCC4(C)C(CCC4(C)C3CCC2C1(C)C)C(N(C)C)C)C=5C=CC=CC5
SuperclassLipids and lipid-like molecules
ClassSteroids and steroid derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)3
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)4
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)1
Molecular weight (mol_MW)488.755
Computed dipole moment(dipole)5.508
Total solvent accessible surface area (SASA)844.24
Hydrophobic component of SASA (FOSA)584.127
Hydrophilic component of SASA (FISA)38.277
Pie component of the SASA (PISA)221.836
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1636.49
Number of hydrogen bond donors (donorHB)1
Number of hydrogen bond acceptors (accptHB)4.5
Free energy of solvation of dipole (dip^2/V)0.0185396
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0053302
Globularity descriptor (glob)0.795502
Predicted polarizability in cubic angstroms (QPpolrz)58.888
Predicted hexadecane/gas partition coefficient (QPlogPC16)15.464
Predicted octanol/gas partition coefficient (QPlogPoct)23.499
Predicted water/gas partition coefficient (QPlogPw)8.535
Predicted octanol/water partition coefficient (QPlogPo/w)7.184
Predicted aqueous solubility (QPlogS)-8.12
Conformation-independent predicted aqueous solubility (CIQPlogS)-6.689
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.625
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1071.07
Predicted brain/blood partition coefficient (QPlogBB)0.318
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)589.466
Predicted skin permeability, log Kp (QPlogKp)-3.122
PM3 calculated ionization potential (IP(ev))8.882
PM3 calculated electron affinity (EA(eV))0.203
Number of likely metabolic reactions (#metab)5
Prediction of binding to human serum albumin (QPlogKhsa)2.042
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)100
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)38.12
Number of nitrogen and oxygen atoms (#NandO)3
Number of violations of Lipinski’s rule of five (RuleOfFive)1
Number of violations of Jorgensen’s rule of three (RuleOfThree)1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
Q9Y5N1HRH3Histamine H3 receptorT64765SwissTargetPrediction
P22303ACHEAcetylcholinesteraseT30082SwissTargetPrediction
Q02083NAAAN-acylsphingosine-amidohydrolase (by homology)T78326SwissTargetPrediction
P21731TBXA2RThromboxane A2 receptorT76198SwissTargetPrediction
P42345MTORSerine/threonine-protein kinase mTORT75243SwissTargetPrediction
P06276BCHEButyrylcholinesteraseT99799SwissTargetPrediction
P30559OXTROxytocin receptor (by homology)T84486SwissTargetPrediction
Q92847GHSRGhrelin receptorT59604SwissTargetPrediction
Q13258PTGDRProstanoid DP receptorT68782SwissTargetPrediction
Q16602CALCRLCalcitonin gene-related peptide type 1 receptorT02226SwissTargetPrediction

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T64765DI0392Somnolence[ICD-11: MG42]Q9Y5N1HRH3
T30082DI0025Alzheimer disease[ICD-11: 8A20]P22303ACHE
T30082DI0166Glaucoma[ICD-11: 9C61]P22303ACHE
T30082DI0282Myasthenia gravis[ICD-11: 8C6Y]P22303ACHE
T30082DI0313Oesophageal/gastroduodenal disorder[ICD-11: DD90]P22303ACHE
T30082DI0332Pediculosis[ICD-11: 1G00]P22303ACHE
T30082DI0421Unspecific substance harmful effect[ICD-11: NE6Z]P22303ACHE
T76198DI0102Coronary atherosclerosis[ICD-11: BA52]P21731TBXA2R
T76198DI0121Diabetic foot ulcer[ICD-11: BD54]P21731TBXA2R
T76198DI0287Myocardial infarction[ICD-11: BA41-BA43]P21731TBXA2R
T76198DI0378Sexual dysfunction[ICD-11: HA00-HA01]P21731TBXA2R
T75243DI0036Arteries/arterioles disorder[ICD-11: BD52]P42345MTOR
T75243DI0085Chronic myelomonocytic leukaemia[ICD-11: 2A40]P42345MTOR
T75243DI0274Multiple myeloma[ICD-11: 2A83]P42345MTOR
T75243DI0361Renal cell carcinoma[ICD-11: 2C90]P42345MTOR
T75243DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P42345MTOR
T75243DI0413Transplant rejection[ICD-11: NE84]P42345MTOR
T99799DI0324Pain[ICD-11: MG30-MG3Z]P06276BCHE
T99799DI0411Tonus and reflex abnormality[ICD-11: MB47]P06276BCHE
T84486DI0009Acute diabete complication[ICD-11: 5A2Y]P30559OXTR
T84486DI0041Autism spectrum disorder[ICD-11: 6A02]P30559OXTR
T84486DI0340Postpartum haemorrhage[ICD-11: JA43]P30559OXTR
T59604DI0087Chronic pain[ICD-11: MG30]Q92847GHSR
T59604DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]Q92847GHSR
T68782DI0102Coronary atherosclerosis[ICD-11: BA52]Q13258PTGDR

Copyright © 2025